Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Fiserv, Inc. related to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by September 22, 2025 [1][3]. Group 1: Allegations Against Fiserv - The complaint alleges that Fiserv and its executives made false or misleading statements regarding the performance of its Clover platform, particularly in relation to forced migrations from the older Payeezy platform [3]. - It is claimed that Clover's revenue growth and gross payment volume (GPV) were artificially inflated due to these forced conversions, masking a slowdown in new merchant acquisitions [3]. - Following the forced migrations, many former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's GPV growth [3]. Group 2: Market Reaction - On April 24, 2025, Fiserv reported a GPV growth of only 8% for Q1 2025, a significant decline from the previous year's growth rates of 14-17%, resulting in an 18.5% drop in stock price [4]. - Further disappointing disclosures on May 15, 2025, indicated continued deceleration in GPV growth, causing an additional 16.2% decline in stock price [4]. - On July 23, 2025, Fiserv lowered its full-year organic growth guidance and reported a decrease in quarterly organic revenue growth in the Merchant segment to 9% year-over-year from 11%, leading to a 13.9% drop in stock price [4].

Group 1 - The core point of the article is that Elon Musk has filed a motion to dismiss the lawsuit brought by the U.S. Securities and Exchange Commission (SEC) regarding his Twitter holdings from 2022 [1] Group 2 - The lawsuit pertains to Musk's ownership stake in Twitter, which was a significant event in the financial and tech sectors [1] - The court documents reveal Musk's legal strategy in response to regulatory scrutiny, highlighting ongoing tensions between high-profile executives and regulatory bodies [1] - This case may have implications for how similar cases are handled in the future, particularly concerning disclosures and ownership stakes in publicly traded companies [1]

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. due to allegations of misleading statements regarding the company's growth and the impact of its CEO's health on business performance [1][4]. Company Performance - C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health problems [5]. - Following the announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of approximately 25.58% in just one day [6]. Legal Proceedings - The class action lawsuit, John Liggett Sr. v. C3.ai, Inc., was initiated in the United States District Court for the Northern District of California, targeting individuals who purchased C3.ai securities between February 26, 2025, and August 8, 2025 [1][4]. - Investors who suffered losses in C3.ai securities have until October 21, 2025, to request to be appointed as lead plaintiff in the case [6].

Core Viewpoint - Nutex Health Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, following a significant surge in its share price and subsequent allegations of fraudulent activities related to its revenue reporting [1][3]. Group 1: Share Price Surge and Allegations - On July 22, 2025, Blue Orca Capital published a report claiming that Nutex's recent 20-fold share price increase was artificially inflated by a third-party vendor, HaloMD, which allegedly facilitated inflated billing awards [3]. - The report indicated that multiple federal lawsuits have been filed against HaloMD, alleging a fraudulent scheme that siphoned millions from insurers, raising doubts about the legitimacy of Nutex's reported revenue [3]. - Following the report, Nutex's share price fell by $11.18, approximately 10.05%, from $111.19 on July 21, 2025, to $100.01 on July 22, 2025 [3]. Group 2: Delay in Financial Reporting - On August 14, 2025, Nutex announced a delay in filing its quarterly financial statements for the period ending June 30, 2025, due to incomplete accounting adjustments [4]. - This announcement led to a further decline in Nutex's share price by $18.22, or approximately 16.39%, from $111.13 on August 14, 2025, to close at $92.91 on August 15, 2025 [4].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against BellRing Brands, Inc. regarding possible violations of federal securities laws and unlawful business practices [1] Group 1: Company Performance - On May 5, 2025, BellRing announced that several key retailers had lowered their weeks of supply on hand starting in Q2 2023, which would negatively impact Q3 2025 growth. The company also stated it would expand promotions to boost sales and offset reductions in retailer trade inventory levels [3] - Following this announcement, BellRing's share price fell by $13.96, approximately 18%, from $77.34 on May 5, 2025, to close at $63.38 on May 6, 2025 [3] - On August 4, 2025, BellRing reported disappointing quarterly consumption of Premier Protein RTD Shakes, which did not meet expectations of outpacing shipments due to retailer destocking. This led to a share price decline of $17.46, or approximately 33%, from $53.64 on August 4, 2025, to close at $36.18 on August 5, 2025 [4] Group 2: Legal Investigation - The investigation by Kirby McInerney LLP focuses on whether BellRing and/or its officers have engaged in unlawful business practices or violated federal securities laws [1] - The law firm has a history of successful recoveries in securities litigation, totaling billions of dollars for shareholders [7]

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1] Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2] - The company's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant decline of 53.2% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A class action lawsuit has been initiated against Altimmune, Inc. following disappointing results from its Phase 2b MASH trial of Pemvidutide, leading to a significant drop in the company's stock price [1][3][4]. Company Overview - Altimmune, Inc. is a biopharmaceutical company focused on developing treatments for liver diseases, including MASH [3]. Legal Proceedings - The lawsuit, Dave Collier v. Altimmune, Inc., was filed in the United States District Court for the District of Maryland, targeting all individuals who purchased Altimmune securities between August 10, 2023, and June 25, 2025 [1]. - Investors have until October 6, 2025, to request to be appointed as lead plaintiff in the case [4]. Trial Results - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [3]. - The company had previously set inflated expectations for the trial results, which were not met due to a higher-than-expected placebo response [3]. Stock Performance - Following the announcement of the trial results, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [4].

Core Viewpoint - Holzer & Holzer, LLC is investigating Barnes & Noble Education, Inc. for potential non-compliance with federal securities laws following the company's disclosure of an inability to file its Annual Report on Form 10-K and a possible overstatement of accounts receivable by up to $23.0 million as of May 3, 2025 [1] Group 1 - Barnes & Noble disclosed on July 18, 2025, that it could not file its Annual Report on Form 10-K for the fiscal year ended May 3, 2025, without unreasonable effort or expense [1] - The company management believes there may be a potential overstatement of up to $23.0 million in its accounts receivable balance as of the fiscal year-end [1] - Following this disclosure, the stock price of Barnes & Noble dropped significantly [1]

Core Viewpoint - Holzer & Holzer, LLC is investigating whether RH complied with federal securities laws following allegations that the company's "demand metric" is misleading, which has resulted in a drop in the stock price [1]. Group 1: Allegations and Impact - Hunterbrook Media published a report on January 24, 2025, claiming that RH's growth in "demand" does not align with its growth in deferred revenue, a standard metric, suggesting potential discrepancies in reporting [1]. - The publication of the report led to a decline in RH's stock price, indicating a negative market reaction to the allegations [1]. Group 2: Legal Representation - Holzer & Holzer, LLC is encouraging investors who purchased RH stock and experienced losses to contact their legal team to discuss potential legal rights [2]. - The firm specializes in representing shareholders and investors in litigation, including class action and derivative litigation, and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vestis Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's growth prospects and business performance [3][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $75,000 in Vestis between May 2, 2024, and May 6, 2025, to contact them to discuss their legal options [1]. - There is an August 8, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Vestis [3]. - The complaint alleges that Vestis and its executives concealed material adverse facts regarding the company's ability to grow its business and execute strategic initiatives [5]. Group 2: Financial Performance and Stock Impact - On May 7, 2025, Vestis announced disappointing financial results for Q2 2025, withdrew its revenue guidance for the full fiscal year, and provided lower-than-expected guidance for Q3 2025 [6]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in customer volume [6]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [6].